FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W186667078> ?p ?o ?g. }

• W186667078 endingPage "326" @default.
• W186667078 startingPage "324" @default.
• W186667078 abstract "Wild-type p53 is normally expressed at low levels and inactive due to the action of MDM2, an E3 ubiquitin ligase that binds p53 and promotes its degradation [1,2]. However, p53 is stabilized in response to various stresses, such as DNA damage or inappropriate oncogene signaling, that might otherwise predispose a normal cell toward tumorigenesis [3]. The stress-induced stabilization of p53 results from disruption of p53-MDM2 binding. The majority of stabilized p53 accumulates in the nucleus where it functions as a transcription factor, activating expression of genes that induce either apoptosis or cell cycle arrests that can be either transient (quiescence) or permanent (senescence). Thus, p53 eliminates cells with potentially cancer-promoting lesions by inhibiting their growth or causing them to die. mTOR is a cytoplasmic kinase whose activity is often elevated in cancer [4]. mTOR converts signals from activated growth factor receptors into downstream events that promote cell proliferation and survival. Previous studies have demonstrated cross-talk between the p53 and mTOR signaling pathways. For example, p53 can activate expression of several genes, including TSC2, PTEN, IGF-BP3, and others, whose protein products can directly or indirectly inhibit mTOR activity [5]. These observations make sense given that p53 is a tumor suppressor and mTOR has more an oncogenic role in promoting cancer cell survival and proliferation. However, more recent studies indicate that the outcome of mTOR signaling can be context-dependent. Thus, while mTOR signaling promotes proliferation and survival under normal conditions, mTOR signaling can promote senescence under conditions in which the cell cycle is blocked [6,7]. These observations support mTOR as a hub for receipt of multiple inputs that ultimately determine cell fate. When conditions are favorable mTOR activation promotes proliferation and survival, however, in the context of conflicting signals (e.g. growth factor signaling vs. cell cycle arrest), the effect of mTOR activation is permanent cell cycle exit (senescence). P21 is a cyclin-cdk inhibitor, transcriptional target of p53, and potent inducer of senescence [8,9]. Blagosklonny and colleagues noted that in some cases p53 induction did not induce senescence while ectopic expression of p21 did [10]. This led to them to question the role of p53 in the senescence program, and whether p53 may actively suppress senescence. To address this, they used a cell line in which p21 was expressed from an inducible (IPTG-driven) promoter [11]. In this cell line, transient p21 expression induced by IPTG caused the cells to undergo a senescent arrest characterized by flat-cell phenotype, expression of senescence-associated beta galactosidase, and a complete loss of proliferative potential after IPTG removal [12]. To test the effect of p53 on this senescent arrest, the authors first induced p21 by IPTG, and then induced p53 expression in the same cells by addition of Nutlin-3a, a small molecule MDM2 antagonist and potent p53 stabilizer. Remarkably, cells in which p53 was induced by Nutlin-3a were able to resume cycling and fully recover after IPTG removal. These results indicated that p53 expression converted the senescence response in these cells to quiescence. The suppression of senescence they observed was associated with p53-dependent inhibition of mTOR activity [12]. In the current issue of Aging, Korotchkina et al. [13] demonstrate that shRNA-mediated knockdown of TSC2, a negative regulator of mTOR and p53 target gene [5], imposed senescence in these Nutlin-3a treated cells. The results support a model in which p53 can suppress senescence through upregulation of TSC2 and inhibition of mTOR." @default.
• W186667078 created "2016-06-24" @default.
• W186667078 creator A5074352836 @default.
• W186667078 date "2010-06-27" @default.
• W186667078 modified "2023-09-23" @default.
• W186667078 title "Decision-making by p53 and mTOR" @default.
• W186667078 cites W1973288117 @default.
• W186667078 cites W1979262539 @default.
• W186667078 cites W1982695619 @default.
• W186667078 cites W1985683054 @default.
• W186667078 cites W1990815825 @default.
• W186667078 cites W1993263392 @default.
• W186667078 cites W1995741673 @default.
• W186667078 cites W2022431825 @default.
• W186667078 cites W2035188342 @default.
• W186667078 cites W2036092325 @default.
• W186667078 cites W2053874502 @default.
• W186667078 cites W2054311839 @default.
• W186667078 cites W2056530510 @default.
• W186667078 cites W2067473930 @default.
• W186667078 cites W2082979850 @default.
• W186667078 cites W2097933346 @default.
• W186667078 cites W2101428185 @default.
• W186667078 cites W2116009473 @default.
• W186667078 cites W2314722778 @default.
• W186667078 cites W2327372357 @default.
• W186667078 doi "https://doi.org/10.18632/aging.100166" @default.
• W186667078 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2919249" @default.
• W186667078 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20603526" @default.
• W186667078 hasPublicationYear "2010" @default.
• W186667078 type Work @default.
• W186667078 sameAs 186667078 @default.
• W186667078 citedByCount "22" @default.
• W186667078 countsByYear W1866670782012 @default.
• W186667078 countsByYear W1866670782014 @default.
• W186667078 countsByYear W1866670782016 @default.
• W186667078 countsByYear W1866670782018 @default.
• W186667078 crossrefType "journal-article" @default.
• W186667078 hasAuthorship W186667078A5074352836 @default.
• W186667078 hasBestOaLocation W1866670782 @default.
• W186667078 hasConcept C15744967 @default.
• W186667078 hasConcept C41008148 @default.
• W186667078 hasConcept C62478195 @default.
• W186667078 hasConcept C86554907 @default.
• W186667078 hasConcept C86803240 @default.
• W186667078 hasConcept C95444343 @default.
• W186667078 hasConceptScore W186667078C15744967 @default.
• W186667078 hasConceptScore W186667078C41008148 @default.
• W186667078 hasConceptScore W186667078C62478195 @default.
• W186667078 hasConceptScore W186667078C86554907 @default.
• W186667078 hasConceptScore W186667078C86803240 @default.
• W186667078 hasConceptScore W186667078C95444343 @default.
• W186667078 hasIssue "6" @default.
• W186667078 hasLocation W1866670781 @default.
• W186667078 hasLocation W1866670782 @default.
• W186667078 hasLocation W1866670783 @default.
• W186667078 hasLocation W1866670784 @default.
• W186667078 hasOpenAccess W186667078 @default.
• W186667078 hasPrimaryLocation W1866670781 @default.
• W186667078 hasRelatedWork W1974250949 @default.
• W186667078 hasRelatedWork W1978608178 @default.
• W186667078 hasRelatedWork W2011233201 @default.
• W186667078 hasRelatedWork W2031281657 @default.
• W186667078 hasRelatedWork W2127789666 @default.
• W186667078 hasRelatedWork W2358668433 @default.
• W186667078 hasRelatedWork W2390279801 @default.
• W186667078 hasRelatedWork W2748952813 @default.
• W186667078 hasRelatedWork W2899084033 @default.
• W186667078 hasRelatedWork W3188367623 @default.
• W186667078 hasVolume "2" @default.
• W186667078 isParatext "false" @default.
• W186667078 isRetracted "false" @default.
• W186667078 magId "186667078" @default.
• W186667078 workType "article" @default.